However, one must speculate that due to the lack of routine screening for extramedullary AML at diagnosis, there might be a considerable amount of unknown extramedullary AML at diagnosis, especially in cases without clinical apparent extramedullary manifestations, for which LOX could also be a potential marker for prognosis. This evidence concerns the gene LOX and acute myeloid leukemia.